Barriers and facilitators to ART adherence among ART non-adherence people living with HIV in Cameroon: A qualitative phenomenological study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
25
09
2022
accepted:
07
08
2023
medline:
14
9
2023
pubmed:
12
9
2023
entrez:
12
9
2023
Statut:
epublish
Résumé
Antiretroviral therapy (ART) needs to be taken for life with near perfect levels of adherence for it to be effective. Nonetheless, ART non-adherence is still observed in sub-Saharan African (SSA) countries such as Cameroon. The objective of this study was to assess the factors influencing non-adherence and or adherence among people living with HIV (PLWH) who have experienced non-adherence to ART in Cameroon. A descriptive qualitative study of PLWH who have experienced non-adherence with ART in Cameroon was conducted. Data were collected using in-depth interviews. Collected data were analyzed using the NVIVO 12 software. In total, 43 participants participated in this study. The Southwest and Littoral regions each contributed 15 (34.88%) of participants, participants' mean age was 37.1 years (SD: 9.81) and majority 34 (82.93%) were females. ART adherence barriers include those related to patient (forgetfulness, business with other things, unwillingness to swallow drugs daily), medication (side effects), health service (arrogance of caregivers, occasional drug shortages at treatment centre, poor counseling of patient), stigma (fear of status disclosure), use of alternative treatment (traditional medicine, prayers and deliverance), resource limitation (limited food, limited finances), environmental/social (limited or no home support), and political instability (disruption of free circulation by ghost towns, roadblocks and gunshots in some regions). ART adherence facilitators include social support (family and peer support), aligning treatment with patient's daily routines (align ART with schedule of family members), use of reminders (phone alarm, sound of church bell), health sector/caregiver support (messages to patient, financial support, proper counseling), and patient's awareness of HIV status/ART knowledge (awareness of HIV positive status, Knowledge of ART benefits). ART adherence barriers in Cameroon include those related to patient, medication, health service, stigma, use of alternative treatment, resource limitation, environmental/social, and political instability. ART adherence facilitators include social support, aligning treatment with patient's daily routines, use of reminders, health sector/caregiver support, and patient's awareness of HIV status/ART knowledge. Given these barriers and facilitators, continuous information provision and consistent support both from patients' families and caregivers are needed to improve adherence among patients. Further studies including many regions and larger samples using both in-depth and focused group discussions as well as quantitative approaches are required to uncover the burden related to ART non-adherence.
Sections du résumé
BACKGROUND
Antiretroviral therapy (ART) needs to be taken for life with near perfect levels of adherence for it to be effective. Nonetheless, ART non-adherence is still observed in sub-Saharan African (SSA) countries such as Cameroon. The objective of this study was to assess the factors influencing non-adherence and or adherence among people living with HIV (PLWH) who have experienced non-adherence to ART in Cameroon.
METHODS
A descriptive qualitative study of PLWH who have experienced non-adherence with ART in Cameroon was conducted. Data were collected using in-depth interviews. Collected data were analyzed using the NVIVO 12 software.
RESULTS
In total, 43 participants participated in this study. The Southwest and Littoral regions each contributed 15 (34.88%) of participants, participants' mean age was 37.1 years (SD: 9.81) and majority 34 (82.93%) were females. ART adherence barriers include those related to patient (forgetfulness, business with other things, unwillingness to swallow drugs daily), medication (side effects), health service (arrogance of caregivers, occasional drug shortages at treatment centre, poor counseling of patient), stigma (fear of status disclosure), use of alternative treatment (traditional medicine, prayers and deliverance), resource limitation (limited food, limited finances), environmental/social (limited or no home support), and political instability (disruption of free circulation by ghost towns, roadblocks and gunshots in some regions). ART adherence facilitators include social support (family and peer support), aligning treatment with patient's daily routines (align ART with schedule of family members), use of reminders (phone alarm, sound of church bell), health sector/caregiver support (messages to patient, financial support, proper counseling), and patient's awareness of HIV status/ART knowledge (awareness of HIV positive status, Knowledge of ART benefits).
CONCLUSION
ART adherence barriers in Cameroon include those related to patient, medication, health service, stigma, use of alternative treatment, resource limitation, environmental/social, and political instability. ART adherence facilitators include social support, aligning treatment with patient's daily routines, use of reminders, health sector/caregiver support, and patient's awareness of HIV status/ART knowledge. Given these barriers and facilitators, continuous information provision and consistent support both from patients' families and caregivers are needed to improve adherence among patients. Further studies including many regions and larger samples using both in-depth and focused group discussions as well as quantitative approaches are required to uncover the burden related to ART non-adherence.
Identifiants
pubmed: 37699048
doi: 10.1371/journal.pone.0291487
pii: PONE-D-22-26591
pmc: PMC10497158
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0291487Informations de copyright
Copyright: © 2023 Buh et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
PLoS One. 2022 Jun 16;17(6):e0270044
pubmed: 35709223
AIDS Care. 2015;27(3):315-21
pubmed: 25355176
Lancet HIV. 2021 Apr;8(4):e206-e215
pubmed: 33617783
Curr Opin HIV AIDS. 2013 Nov;8(6):528-34
pubmed: 24100873
AIDS Care. 2012;24(6):728-36
pubmed: 22150119
J Assoc Nurses AIDS Care. 2004 Sep-Oct;15(5):30-9
pubmed: 15358923
AIDS Care. 2007 Jul;19(6):811-6
pubmed: 17573602
J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Aug 1;18(4):341-8
pubmed: 9704939
AIDS Care. 2018 Feb;30(2):224-231
pubmed: 28643572
Glob Health Action. 2013 Mar 15;6:19570
pubmed: 23497956
AIDS Behav. 2005 Sep;9(3):355-62
pubmed: 16088365
AIDS Rev. 2013 Jan-Mar;15(1):15-24
pubmed: 23449225
PLoS Med. 2016 Nov 29;13(11):e1002183
pubmed: 27898679
AIDS. 2017 Apr 24;31(7):995-1007
pubmed: 28121707
J Health Psychol. 2010 Oct;15(7):1001-11
pubmed: 20801946
Afr Health Sci. 2022 Sep;22(3):455-462
pubmed: 36910408
Lancet. 2006 Nov 4;368(9547):1587-94
pubmed: 17084759
Front Psychiatry. 2022 Sep 14;13:824062
pubmed: 36186875
HIV Med. 2011 Oct;12(9):562-9
pubmed: 21554524
AIDS Care. 2017 Dec;29(12):1533-1537
pubmed: 28490197
Science. 2013 Feb 22;339(6122):961-5
pubmed: 23430655
PLoS One. 2014 May 14;9(5):e97353
pubmed: 24828585
BMC Public Health. 2017 May 4;17(1):385
pubmed: 28472938
BMC Public Health. 2021 Dec 13;21(1):2274
pubmed: 34903209
Afr J AIDS Res. 2013 Mar;12(1):1-8
pubmed: 25871305
South Afr J HIV Med. 2016 Sep 30;17(1):476
pubmed: 29568618
J Acquir Immune Defic Syndr. 2021 Dec 15;88(5):448-456
pubmed: 34757973
BMC Infect Dis. 2015 Jan 31;15:28
pubmed: 25637106
J Acquir Immune Defic Syndr. 2001 Sep 1;28(1):47-58
pubmed: 11579277
Ann Intern Med. 2011 Aug 16;155(4):209-16
pubmed: 21768555
J Acquir Immune Defic Syndr. 2007 Nov 1;46(3):323-7
pubmed: 17846560
J Antimicrob Chemother. 2009 Apr;63(4):636-40
pubmed: 19153077
Retrovirology. 2008 Feb 01;5:13
pubmed: 18241330
AIDS Behav. 2015 Aug;19(8):1510-26
pubmed: 25096896
Soc Sci Med. 2009 May;68(10):1793-800
pubmed: 19328609
J Health Psychol. 2005 May;10(3):345-58
pubmed: 15857867
J Int AIDS Soc. 2013 Dec 01;16:18927
pubmed: 24314398
AIDS. 2012 Oct 23;26(16):2039-52
pubmed: 22951634
J Int AIDS Soc. 2017 Mar 30;20(1):21437
pubmed: 28406275
J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):e18-e22
pubmed: 27926668
PLoS Med. 2013;10(4):e1001418
pubmed: 23585736
Patient Prefer Adherence. 2016 Mar 15;10:329-37
pubmed: 27042024